Plans call for 12 sites and two advisory boards.
The Multiple Sclerosis Association of America (MSAA) is collaborating with the Chronic Health Improvement Program (CHIRP) at Dartmouth Health and Novartis Pharmaceuticals Corporation to launch the Multiple Sclerosis Implementation Network (MSIN).
The MSIN is a patient-centered, multicenter learning health network designed to help providers support people with multiple sclerosis (MS) through research collaboration and data sharing. Goals of this first-of-its-kind initiative include developing a research-driven data environment; improving patient care, experience, and outcomes by using improvement and implementation approaches; helping to close healthcare disparity gaps by advocating for treatment access for all people living with MS across all practice settings and locations; supporting MS care providers; and improving clinical outcomes for people with MS.
During the first year, the initiative will enroll 12 sites selected to represent geographic, practice (general neurologist versus MS specialist), and patient demographic diversity. The participating centers will be linked with healthcare professionals throughout the United States. The hope is that by sharing de-identified patient data and outcomes within the network, care centers and practitioners will learn more about ways to improve care and health outcomes while simultaneously contributing to research.
The project will receive guidance from two advisory boards, one made up of people with MS and their care partners, and the other includes healthcare professionals, researchers, and advocates.
Details regarding the MSIN were presented in an e-poster at the 17th World Congress on Controversies in Neurology in Dubrovnik, Croatia, in March 2023.
Brant Oliver, Ph.D., M.S., M.P.H., director of CHIRP and associate professor at Geisel School of Medicine at Dartmouth, will serve as principal investigator. He said in a press release, “MSIN is an exciting forward-thinking, cutting-edge initiative that is first-of-its-kind in multiple sclerosis. It will leverage the very best of what improvement, implementation science, care experience, and futuristic technology can accomplish. We will use a learning health network approach to create an environment of support and collaboration, which will amplify our ability to simultaneously improve care, implement evidence-based interventions, and study MS care in a way that is driven by the needs and voices of people with MS. I am honored to serve as principal investigator for this promising initiative.”
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More
Ozanimod Shows Sustained Efficacy in Long-term Study for Multiple Sclerosis Treatment
March 11th 2024Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.
Read More